Litcius/Paper detail

The impact of the <scp>COVID</scp> ‐19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience

Paolo Gisondi, Paola Facheris, Paolo Dapavo, Stefano Piaserico, Andrea Conti, Luigi Naldi, Simone Cazzaniga, Piergiorgio Malagoli, Antonio Costanzo

2020British Journal of Dermatology114 citationsDOIOpen Access PDF

Abstract

The “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2) has spread over the four continents, causing the respiratory manifestations of Coronavirus disease-19 (COVID-19) and satisfying the epidemiological criteria for a pandemic [1]. As of April 1, 2020, more than one million COVID-19 positive cases have been identified and more than 54,000 deaths have occurred worldwide [2]. In Italy, 110,574 positive cases, 49,285 hospitalized patients and 13,155 deaths out of a population of 60,359,546 inhabitants, have been reported, respectively [3]. The highest number of deaths occurred in the northern Italian regions, i.e. Lombardy, Emilia-Romagna, Veneto and Piedmont [3].

Topics & Concepts

MedicinePsoriasisPlaque psoriasisEpidemiologyPandemicCoronavirus disease 2019 (COVID-19)PneumoniaObservational studyPopulationRetrospective cohort studyInternal medicineDermatologyPediatricsDiseaseInfectious disease (medical specialty)Environmental healthCOVID-19 and healthcare impactsPsoriasis: Treatment and PathogenesisCOVID-19 Clinical Research Studies